T1	tradename 0 8	ABRAXANE
T3	activeingredient 37 47	paclitaxel
T5	tradename 170 178	ABRAXANE
T7	tradename 242 262	ABRAXANE.  ABRAXANE
T9	nanoparticle 291 315	paclitaxel protein-bound
T11	nanoparticle 317 326	particles
T13	corecomposition 355 368	albumin-bound
T15	fdaapprovaldate 394 398	2005
T17	tradename 502 510	ABRAXANE
T19	activeingredient 787 797	PACLITAXEL
T21	tradename 1085 1093	ABRAXANE
T23	chemoclass 1099 1120	microtubule inhibitor
T25	indication 1154 1178	Metastatic breast cancer
T27	indication 1414 1459	metastatic non-small cell lung cancer (NSCLC)
T29	indication 1603 1644	Metastatic adenocarcinoma of the pancreas
T31	indication 1785 1810	Metastatic Breast Cancer:
T33	tradename 1833 1841	ABRAXANE
T35	dose 1845 1854	260 mg/m2
T37	routeofadministration 1855 1868	intravenously
T39	indication 1907 1934	Non-Small Cell Lung Cancer:
T41	tradename 1957 1965	ABRAXANE
T43	dose 1969 1978	100 mg/m2
T45	routeofadministration 1979 1992	intravenously
T47	tradename 2123 2132	ABRAXANE.
T49	indication 2140 2171	Adenocarcinoma of the Pancreas:
T51	tradename 2194 2202	ABRAXANE
T53	dose 2206 2215	125 mg/m2
T55	routeofadministration 2216 2229	intravenously
T57	tradename 2373 2382	ABRAXANE.
T59	tradename 2408 2416	ABRAXANE
T61	tradename 2500 2508	ABRAXANE
T63	indication 2526 2567	metastatic adenocarcinoma of the pancreas
T65	indication 2640 2681	metastatic adenocarcinoma of the pancreas
T67	activeingredient 3240 3250	paclitaxel
T69	corecomposition 3265 3278	albumin-bound
T71	tradename 3508 3517	ABRAXANE.
T73	tradename 3599 3607	ABRAXANE
T75	tradename 3874 3882	ABRAXANE
T77	tradename 3926 3934	ABRAXANE
T79	tradename 4131 4139	ABRAXANE
T81	tradename 4212 4220	ABRAXANE
T83	activeingredient 4387 4397	paclitaxel
T85	tradename 4494 4502	ABRAXANE
T87	tradename 4747 4756	ABRAXANE.
T89	tradename 4806 4815	ABRAXANE.
T91	indication 4954 4978	metastatic breast cancer
T93	adversereaction 4983 4991	alopecia
T95	adversereaction 4993 5004	neutropenia
T97	adversereaction 5006 5024	sensory neuropathy
T99	adversereaction 5026 5038	abnormal ECG
T101	adversereaction 5040 5056	fatigue/asthenia
T103	adversereaction 5058 5076	myalgia/arthralgia
T105	adversereaction 5078 5091	AST elevation
T107	adversereaction 5093 5123	alkaline phosphatase elevation
T109	adversereaction 5125 5131	anemia
T111	adversereaction 5133 5139	nausea
T113	adversereaction 5141 5151	infections
T115	adversereaction 5157 5166	diarrhea.
T117	indication 5226 5231	NSCLC
T119	adversereaction 5236 5242	anemia
T121	adversereaction 5244 5255	neutropenia
T123	adversereaction 5257 5273	thrombocytopenia
T125	adversereaction 5275 5283	alopecia
T127	adversereaction 5285 5306	peripheral neuropathy
T129	adversereaction 5308 5314	nausea
T131	adversereaction 5320 5328	fatigue.
T133	tradename 5388 5396	ABRAXANE
T135	indication 5400 5430	adenocarcinoma of the pancreas
T137	adversereaction 5435 5446	neutropenia
T139	adversereaction 5448 5455	fatigue
T141	adversereaction 5457 5478	peripheral neuropathy
T143	adversereaction 5480 5486	nausea
T145	adversereaction 5488 5496	alopecia
T147	adversereaction 5498 5514	peripheral edema
T149	adversereaction 5516 5524	diarrhea
T151	adversereaction 5526 5533	pyrexia
T153	adversereaction 5535 5543	vomiting
T155	adversereaction 5545 5563	decreased appetite
T157	adversereaction 5565 5569	rash
T159	adversereaction 5575 5587	dehydration.
T161	company 5642 5661	Celgene Corporation
T163	tradename 5861 5869	ABRAXANE
T165	indication 6124 6148	Metastatic Breast Cancer
T167	indication 6155 6181	Non-Small Cell Lung Cancer
T169	indication 6188 6218	Adenocarcinoma of the Pancreas
T171	indication 6255 6279	Metastatic Breast Cancer
T173	indication 6287 6313	Non-Small Cell Lung Cancer
T175	indication 6320 6350	Adenocarcinoma of the Pancreas
T177	routeofadministration 6526 6537	Intravenous
T179	corecomposition 6782 6789	Albumin
T181	indication 6899 6923	Metastatic Breast Cancer
T183	indication 6961 6987	Non-Small Cell Lung Cancer
T185	indication 7024 7054	Adenocarcinoma of the Pancreas
T187	tradename 7093 7101	ABRAXANE
T189	activeingredient 7112 7122	Paclitaxel
T191	indication 7596 7620	Metastatic Breast Cancer
T193	indication 7629 7655	Non-Small Cell Lung Cancer
T195	indication 7664 7694	Adenocarcinoma of the Pancreas
T197	tradename 7969 7977	ABRAXANE
T199	nanoparticle 8006 8040	paclitaxel protein-bound particles
T201	corecomposition 8069 8082	albumin-bound
T203	tradename 8126 8134	ABRAXANE
T205	tradename 8454 8462	ABRAXANE
T207	corecomposition 8572 8579	albumin
T209	activeingredient 8588 8598	paclitaxel
T211	activeingredient 8730 8740	PACLITAXEL
T213	indication 8787 8811	Metastatic Breast Cancer
T215	tradename 8813 8821	ABRAXANE
T217	indication 9081 9107	Non-Small Cell Lung Cancer
T219	tradename 9109 9117	ABRAXANE
T221	indication 9183 9220	metastatic non-small cell lung cancer
T223	indication 9338 9368	Adenocarcinoma of the Pancreas
T225	tradename 9370 9378	ABRAXANE
T227	indication 9438 9479	metastatic adenocarcinoma of the pancreas
T229	indication 9550 9574	Metastatic Breast Cancer
T231	indication 9622 9646	metastatic breast cancer
T233	tradename 9728 9736	ABRAXANE
T235	dose 9740 9749	260 mg/m2
T237	routeofadministration 9763 9776	intravenously
T239	frequency 9793 9807	every 3 weeks.
T241	indication 9814 9840	Non-Small Cell Lung Cancer
T243	tradename 9866 9874	ABRAXANE
T245	dose 9878 9887	100 mg/m2
T247	routeofadministration 9907 9918	intravenous
T249	tradename 10060 10068	ABRAXANE
T251	indication 10106 10136	Adenocarcinoma of the Pancreas
T253	tradename 10162 10170	ABRAXANE
T255	dose 10174 10183	125 mg/m2
T257	routeofadministration 10203 10214	intravenous
T259	tradename 10328 10336	ABRAXANE
T261	tradename 10719 10727	ABRAXANE
T263	indication 10745 10786	metastatic adenocarcinoma of the pancreas
T265	tradename 10854 10862	ABRAXANE
T267	tradename 11225 11233	ABRAXANE
T269	indication 11241 11250	MBC NSCLC
T271	indication 11626 11629	MBC
T273	indication 11632 11656	Metastatic Breast Cancer
T275	indication 11658 11663	NSCLC
T277	indication 11666 11693	Non-Small Cell Lung Cancer.
T279	dose 11886 11895	260 mg/m2
T281	indication 11914 11938	metastatic breast cancer
T283	dose 11942 11951	100 mg/m2
T285	indication 11970 11996	non-small cell lung cancer
T287	indication 12287 12311	Metastatic Breast Cancer
T289	adversereaction 12337 12355	severe neutropenia
T291	tradename 12451 12459	ABRAXANE
T293	dose 12498 12507	220 mg/m2
T295	tradename 12534 12546	ABRAXANE. 
T297	adversereaction 12564 12582	severe neutropenia
T299	adversereaction 12586 12611	severe sensory neuropathy
T301	dose 12657 12666	180 mg/m2
T303	adversereaction 12674 12700	Grade 3 sensory neuropathy
T305	tradename 12809 12817	ABRAXANE
T307	tradename 12913 12914	 
T309	indication 12914 12940	Non-Small Cell Lung Cancer
T311	tradename 12960 12968	ABRAXANE
T313	tradename 13599 13607	ABRAXANE
T315	tradename 13664 13672	ABRAXANE
T317	adversereaction 13677 13709	Grade 3-4 peripheral neuropathy.
T319	tradename 13718 13726	ABRAXANE
T321	adversereaction 13779 13800	peripheral neuropathy
T323	indication 14003 14008	NSCLC
T325	tradename 14051 14059	ABRAXANE
T327	tradename 14558 14561	 
T329	indication 14561 14591	Adenocarcinoma of the Pancreas
T331	indication 14632 14662	adenocarcinoma of the pancreas
T333	indication 14773 14803	Adenocarcinoma of the Pancreas
T335	tradename 14817 14825	ABRAXANE
T337	indication 15079 15109	adenocarcinoma of the pancreas
T339	indication 15284 15314	Adenocarcinoma of the Pancreas
T341	tradename 15370 15378	ABRAXANE
T343	indication 16078 16108	adenocarcinoma of the pancreas
T345	indication 16214 16244	Adenocarcinoma of the Pancreas
T347	tradename 16268 16276	ABRAXANE
T349	tradename 16844 16852	ABRAXANE
T351	activeingredient 16910 16920	paclitaxel
T353	tradename 16972 16983	ABRAXANE. 
T355	tradename 17020 17028	ABRAXANE
T357	activeingredient 17189 17199	paclitaxel
T359	tradename 17254 17262	ABRAXANE
T361	adversereaction 17372 17385	extravasation
T363	tradename 17519 17527	ABRAXANE
T365	adversereaction 17582 17608	infusion-related reactions
T367	adversereaction 17666 17692	hypersensitivity reactions
T369	tradename 17748 17757	ABRAXANE.
T371	tradename 17848 17860	ABRAXANE. 
T373	tradename 17922 17930	ABRAXANE
T375	routeofadministration 18034 18045	Intravenous
T377	tradename 18063 18071	ABRAXANE
T379	activeingredient 19096 19107	paclitaxel.
T381	tradename 19611 19619	ABRAXANE
T383	tradename 19867 19875	ABRAXANE
T385	tradename 20132 20140	ABRAXANE
T387	tradename 20416 20424	ABRAXANE
T389	tradename 21066 21074	ABRAXANE
T391	activeingredient 21401 21411	paclitaxel
T393	corecomposition 21426 21439	albumin-bound
T395	tradename 21512 21521	 ABRAXANE
T397	tradename 21678 21686	ABRAXANE
T399	adversereaction 21785 21808	Bone marrow suppression
T401	adversereaction 21820 21832	neutropenia)
T403	tradename 21883 21895	ABRAXANE. 
T405	adversereaction 21916 21937	Grade 3-4 neutropenia
T407	indication 21971 22001	metastatic breast cancer (MBC)
T409	indication 22024 22058	non-small cell lung cancer (NSCLC)
T411	adversereaction 22117 22130	myelotoxicity
T413	indication 22224 22228	MBC)
T415	indication 22256 22261	NSCLC
T417	indication 22270 22288	pancreatic cancer)
T419	tradename 22310 22318	ABRAXANE
T421	tradename 22505 22513	ABRAXANE
T423	tradename 22542 22550	ABRAXANE
T425	indication 22597 22600	MBC
T427	indication 22604 22610	NSCLC.
T429	indication 22629 22632	MBC
T431	tradename 22679 22687	ABRAXANE
T433	indication 22813 22818	NSCLC
T435	tradename 22938 22946	ABRAXANE
T437	indication 23253 23283	adenocarcinoma of the pancreas
T439	tradename 23294 23302	ABRAXANE
T441	adversereaction 23677 23695	Sensory neuropathy
T443	adversereaction 23788 23819	Grade 1 or 2 sensory neuropathy
T445	adversereaction 23879 23905	Grade 3 sensory neuropathy
T447	tradename 23925 23933	ABRAXANE
T449	indication 23981 24005	metastatic breast cancer
T451	indication 24050 24055	NSCLC
T453	tradename 24137 24145	ABRAXANE
T455	adversereaction 24191 24197	Sepsis
T457	adversereaction 24199 24205	Sepsis
T459	adversereaction 24249 24260	neutropenia
T461	tradename 24274 24282	ABRAXANE
T463	co-administereddrug 24303 24315	gemcitabine.
T465	adversereaction 24521 24540	febrile neutropenia
T467	tradename 24552 24560	ABRAXANE
T469	co-administereddrug 24565 24576	gemcitabine
T471	adversereaction 24710 24721	Pneumonitis
T473	adversereaction 24723 24734	Pneumonitis
T475	tradename 24811 24819	ABRAXANE
T477	co-administereddrug 24840 24852	gemcitabine.
T479	adversereaction 24896 24907	pneumonitis
T481	tradename 24922 24930	ABRAXANE
T483	co-administereddrug 24935 24946	gemcitabine
T485	adversereaction 24978 24990	pneumonitis.
T487	adversereaction 25061 25072	pneumonitis
T489	tradename 25113 25121	ABRAXANE
T491	co-administereddrug 25126 25138	gemcitabine.
T493	adversereaction 25145 25161	Hypersensitivity
T495	adversereaction 25190 25216	hypersensitivity reactions
T497	adversereaction 25228 25250	anaphylactic reactions
T499	adversereaction 25306 25331	hypersensitivity reaction
T501	tradename 25335 25343	ABRAXANE
T503	activeingredient 25451 25461	paclitaxel
T505	tradename 25522 25530	ABRAXANE
T507	tradename 25798 25806	ABRAXANE
T509	tradename 25910 25918	ABRAXANE
T511	indication 25955 25996	metastatic adenocarcinoma of the pancreas
T513	corecomposition 26307 26314	Albumin
T515	tradename 26324 26332	ABRAXANE
T517	corecomposition 26342 26349	albumin
T519	corecomposition 26712 26720	albumin.
T521	tradename 26745 26753	ABRAXANE
T523	activeingredient 26834 26844	paclitaxel
T525	corecomposition 26859 26872	albumin-bound
T527	tradename 27212 27221	ABRAXANE.
T529	tradename 27487 27495	ABRAXANE
T531	tradename 27615 27623	ABRAXANE
T533	tradename 28024 28032	ABRAXANE
T535	indication 28036 28060	metastatic breast cancer
T537	adversereaction 28065 28073	alopecia
T539	adversereaction 28075 28086	neutropenia
T541	adversereaction 28088 28106	sensory neuropathy
T543	adversereaction 28108 28120	abnormal ECG
T545	adversereaction 28122 28138	fatigue/asthenia
T547	adversereaction 28140 28158	myalgia/arthralgia
T549	adversereaction 28160 28173	AST elevation
T551	adversereaction 28175 28205	alkaline phosphatase elevation
T553	adversereaction 28207 28213	anemia
T555	adversereaction 28215 28221	nausea
T557	adversereaction 28223 28233	infections
T559	adversereaction 28239 28247	diarrhea
T561	tradename 28332 28340	ABRAXANE
T563	co-administereddrug 28361 28372	carboplatin
T565	indication 28377 28403	non-small cell lung cancer
T567	adversereaction 28408 28414	anemia
T569	adversereaction 28416 28427	neutropenia
T571	adversereaction 28429 28445	thrombocytopenia
T573	adversereaction 28447 28455	alopecia
T575	adversereaction 28457 28478	peripheral neuropathy
T577	adversereaction 28480 28486	nausea
T579	adversereaction 28492 28499	fatigue
T581	tradename 28576 28584	ABRAXANE
T583	co-administereddrug 28605 28616	carboplatin
T585	indication 28621 28647	non-small cell lung cancer
T587	adversereaction 28652 28658	anemia
T589	adversereaction 28668 28677	pneumonia
T591	tradename 28761 28769	ABRAXANE
T593	adversereaction 28774 28785	neutropenia
T595	adversereaction 28792 28808	thrombocytopenia
T597	adversereaction 28819 28840	peripheral neuropathy
T599	tradename 28913 28921	ABRAXANE
T601	adversereaction 28926 28937	neutropenia
T603	adversereaction 28945 28961	thrombocytopenia
T605	adversereaction 28973 28979	anemia
T607	tradename 29057 29065	ABRAXANE
T609	adversereaction 29077 29088	neutropenia
T611	adversereaction 29096 29112	thrombocytopenia
T613	adversereaction 29124 29130	anemia
T615	tradename 29176 29184	ABRAXANE
T617	co-administereddrug 29205 29216	gemcitabine
T619	indication 29221 29246	pancreatic adenocarcinoma
T621	tradename 29377 29385	ABRAXANE
T623	adversereaction 29390 29401	neutropenia
T625	adversereaction 29403 29410	fatigue
T627	adversereaction 29412 29433	peripheral neuropathy
T629	adversereaction 29435 29441	nausea
T631	adversereaction 29443 29451	alopecia
T633	adversereaction 29453 29469	peripheral edema
T635	adversereaction 29471 29479	diarrhea
T637	adversereaction 29481 29488	pyrexia
T639	adversereaction 29490 29498	vomiting
T641	adversereaction 29500 29518	decreased appetite
T643	adversereaction 29520 29524	rash
T645	adversereaction 29530 29542	dehydration.
T647	tradename 29589 29597	ABRAXANE
T649	adversereaction 29640 29647	pyrexia
T651	adversereaction 29654 29665	dehydration
T653	adversereaction 29672 29681	pneumonia
T655	adversereaction 29691 29699	vomiting
T657	tradename 29784 29792	ABRAXANE
T659	adversereaction 29797 29818	peripheral neuropathy
T661	adversereaction 29825 29832	fatigue
T663	adversereaction 29842 29858	thrombocytopenia
T665	tradename 29932 29940	ABRAXANE
T667	adversereaction 29945 29956	neutropenia
T669	adversereaction 29967 29988	peripheral neuropathy
T671	tradename 30065 30073	ABRAXANE
T673	adversereaction 30085 30096	neutropenia
T675	adversereaction 30104 30120	thrombocytopenia
T677	adversereaction 30128 30135	fatigue
T679	adversereaction 30142 30163	peripheral neuropathy
T681	adversereaction 30171 30177	anemia
T683	adversereaction 30187 30195	diarrhea
T685	indication 30238 30262	Metastatic Breast Cancer
T687	tradename 30407 30415	ABRAXANE
T689	activeingredient 30419 30429	paclitaxel
T691	indication 30461 30486	metastatic breast cancer.
T693	tradename 30656 30666	ABRAXANE 
T695	activeingredient 30697 30707	Paclitaxel
T697	adversereaction 30760 30771	Neutropenia
T699	adversereaction 30832 30848	Thrombocytopenia
T701	adversereaction 30907 30913	Anemia
T703	adversereaction 30956 30966	Infections
T705	adversereaction 30975 30994	Febrile Neutropenia
T707	adversereaction 31001 31019	Neutropenic Sepsis
T709	adversereaction 31032 31040	Bleeding
T711	indication 31134 31151	Metastatic Breast
T713	tradename 31153 31154	 
T715	indication 31154 31160	Cancer
T717	tradename 31228 31236	ABRAXANE
T719	dose 31237 31246	260 mg/m2
T721	activeingredient 31268 31278	Paclitaxel
T723	dose 31289 31298	175 mg/m2
T725	tradename 31318 31319	 
T727	adversereaction 31319 31335	Hypersensitivity
T729	adversereaction 31337 31346	Reactionc
T731	adversereaction 31435 31446	Bradycardia
T733	adversereaction 31464 31475	Hypotension
T735	adversereaction 31483 31512	Severe Cardiovascular Eventsd
T737	adversereaction 31518 31530	Abnormal ECG
T739	adversereaction 31602 31607	Cough
T741	adversereaction 31615 31622	Dyspnea
T743	adversereaction 31630 31648	Sensory Neuropathy
T745	adversereaction 31694 31701	Myalgia
T747	adversereaction 31704 31714	Arthralgia
T749	adversereaction 31759 31767	Asthenia
T751	adversereaction 31812 31833	Fluid Retention/Edema
T753	adversereaction 31898 31904	Nausea
T755	adversereaction 31966 31974	Vomiting
T757	adversereaction 32028 32036	Diarrhea
T759	adversereaction 32090 32099	Mucositis
T761	tradename 32152 32153	 
T763	adversereaction 32153 32161	Alopecia
T765	adversereaction 32211 32231	Bilirubin Elevations
T767	adversereaction 32240 32271	Alkaline Phosphatase Elevations
T769	adversereaction 32312 32335	Injection Site Reaction
T771	activeingredient 32445 32455	Paclitaxel
T773	adversereaction 32547 32563	hypersensitivity
T775	adversereaction 32571 32579	flushing
T777	adversereaction 32581 32588	dyspnea
T779	adversereaction 32590 32600	chest pain
T781	adversereaction 32602 32614	hypotension)
T783	adversereaction 32770 32781	Neutropenia
T785	indication 32839 32863	metastatic breast cancer
T787	dose 32991 33000	260 mg/m2
T789	activeingredient 33039 33049	paclitaxel
T791	dose 33073 33082	175 mg/m2
T793	adversereaction 33085 33097	Pancytopenia
T795	tradename 33219 33231	ABRAXANE. 
T797	tradename 33428 33436	ABRAXANE
T799	tradename 33563 33571	ABRAXANE
T801	activeingredient 33626 33636	paclitaxel
T803	corecomposition 33656 33663	albumin
T805	tradename 34038 34046	ABRAXANE
T807	tradename 34989 35000	ABRAXANE. 
T809	tradename 35130 35138	ABRAXANE
T811	tradename 35221 35229	ABRAXANE
T813	tradename 35398 35406	ABRAXANE
T815	tradename 35811 35819	ABRAXANE
T817	tradename 36124 36132	ABRAXANE
T819	tradename 36270 36278	ABRAXANE
T821	activeingredient 36312 36322	paclitaxel
T823	indication 36785 36811	Non-Small Cell Lung Cancer
T825	tradename 36851 36860	ABRAXANE/
T827	activeingredient 36897 36907	paclitaxel
T829	indication 37040 37074	non-small cell lung cancer (NSCLC)
T831	tradename 37125 37133	ABRAXANE
T833	routeofadministration 37157 37168	intravenous
T835	dose 37207 37216	100 mg/m2
T837	activeingredient 37262 37272	Paclitaxel
T839	routeofadministration 37306 37317	intravenous
T841	dose 37353 37362	200 mg/m2
T843	routeofadministration 37481 37494	intravenously
T845	tradename 37545 37554	ABRAXANE/
T847	activeingredient 37554 37564	paclitaxel
T849	activeingredient 37595 37605	paclitaxel
T851	tradename 38092 38100	ABRAXANE
T853	activeingredient 38112 38122	paclitaxel
T855	tradename 38346 38354	ABRAXANE
T857	tradename 38588 38596	ABRAXANE
T859	activeingredient 38634 38644	paclitaxel
T861	tradename 38869 38877	ABRAXANE
T863	dose 38879 38888	100 mg/m2
T865	frequency 38889 38896	weekly)
T867	activeingredient 38915 38925	Paclitaxel
T869	dose 38937 38946	200 mg/m2
T871	frequency 38947 38961	every 3 weeks)
T873	tradename 39149 39158	ABRAXANE/
T875	activeingredient 39212 39222	paclitaxel
T877	activeingredient 39288 39298	paclitaxel
T879	tradename 39544 39552	ABRAXANE
T881	activeingredient 39631 39641	paclitaxel
T883	tradename 39876 39884	ABRAXANE
T885	dose 39886 39895	100 mg/m2
T887	frequency 39896 39903	weekly)
T889	activeingredient 39926 39936	Paclitaxel
T891	dose 39948 39957	200 mg/m2
T893	frequency 39958 39972	every 3 weeks)
T895	tradename 40501 40509	ABRAXANE
T897	tradename 40782 40794	ABRAXANE.  
T899	indication 40828 40858	Adenocarcinoma of the Pancreas
T901	tradename 40921 40929	ABRAXANE
T903	indication 41030 41071	metastatic adenocarcinoma of the pancreas
T905	tradename 41216 41225	ABRAXANE/
T907	tradename 41380 41389	ABRAXANE/
T909	tradename 41481 41489	ABRAXANE
T911	tradename 41691 41699	ABRAXANE
T913	tradename 41898 41907	ABRAXANE/
T915	tradename 41924 41933	ABRAXANE(
T917	dose 41933 41943	125 mg/m2)
T919	tradename 42121 42130	ABRAXANE/
T921	tradename 42238 42247	ABRAXANE/
T923	tradename 42346 42355	ABRAXANE/
T925	tradename 42548 42556	ABRAXANE
T927	tradename 42774 42783	ABRAXANE/
T929	tradename 42838 42846	ABRAXANE
T931	dose 42848 42858	125 mg/m2)
T933	tradename 44432 44441	ABRAXANE/
T935	tradename 44507 44515	ABRAXANE
T937	dose 44517 44527	125 mg/m2)
T939	indication 45096 45126	adenocarcinoma of the pancreas
T941	tradename 45140 45149	ABRAXANE/
T943	tradename 45460 45469	ABRAXANE/
T945	tradename 45670 45678	ABRAXANE
T947	tradename 45717 45725	ABRAXANE
T949	tradename 45836 45852	ABRAXANE-treated
T951	tradename 45910 45918	ABRAXANE
T953	tradename 45995 46004	ABRAXANE/
T955	tradename 46288 46297	ABRAXANE/
T957	tradename 46394 46402	ABRAXANE
T959	tradename 46468 46476	ABRAXANE
T961	activeingredient 46487 46497	Paclitaxel
T963	tradename 46646 46657	ABRAXANE. 
T965	activeingredient 46908 46918	paclitaxel
T967	tradename 46959 46970	ABRAXANE. 
T969	tradename 47075 47087	ABRAXANE. 
T971	tradename 47098 47106	ABRAXANE
T973	activeingredient 47161 47171	paclitaxel
T975	corecomposition 47191 47198	albumin
T977	tradename 47352 47364	ABRAXANE. 
T979	tradename 47614 47622	ABRAXANE
T981	activeingredient 47795 47805	paclitaxel
T983	tradename 47853 47865	ABRAXANE.  
T985	activeingredient 48112 48122	paclitaxel
T987	tradename 48204 48215	ABRAXANE. 
T989	tradename 48312 48320	ABRAXANE
T991	activeingredient 48581 48591	paclitaxel
T993	tradename 48633 48641	ABRAXANE
T995	tradename 48798 48806	ABRAXANE
T997	activeingredient 48958 48968	paclitaxel
T999	tradename 49111 49123	ABRAXANE. 
T1001	tradename 49202 49210	ABRAXANE
T1003	activeingredient 49421 49431	paclitaxel
T1005	activeingredient 49510 49520	paclitaxel
T1007	activeingredient 49717 49727	paclitaxel
T1009	tradename 49944 49956	ABRAXANE. 
T1011	activeingredient 50313 50323	paclitaxel
T1013	tradename 50399 50407	ABRAXANE
T1015	activeingredient 50458 50468	paclitaxel
T1017	activeingredient 50673 50683	paclitaxel
T1019	tradename 50767 50775	ABRAXANE
T1021	tradename 51265 51277	ABRAXANE. 
T1023	tradename 51335 51343	ABRAXANE
T1025	tradename 51669 51680	ABRAXANE. 
T1027	activeingredient 51698 51708	paclitaxel
T1029	corecomposition 51723 51736	albumin-bound
T1031	dose 51811 51818	6 mg/m2
T1033	dose 52353 52360	3 mg/m2
T1035	activeingredient 52487 52497	paclitaxel
T1037	activeingredient 52525 52535	Paclitaxel
T1039	tradename 52924 52932	ABRAXANE
T1041	tradename 53058 53066	ABRAXANE
T1043	indication 53088 53112	metastatic breast cancer
T1045	tradename 53261 53272	ABRAXANE. 
T1047	tradename 53329 53337	ABRAXANE
T1049	indication 53386 53412	non-small cell lung cancer
T1051	tradename 53856 53864	ABRAXANE
T1053	tradename 54304 54312	ABRAXANE
T1055	activeingredient 54533 54543	paclitaxel
T1057	tradename 54650 54658	ABRAXANE
T1059	tradename 54748 54756	ABRAXANE
T1061	indication 54964 55005	metastatic adenocarcinoma of the pancreas
T1063	tradename 55156 55164	ABRAXANE
T1065	tradename 55562 55570	ABRAXANE
T1067	tradename 55734 55743	 ABRAXANE
T1069	nanoparticle 55771 55805	paclitaxel protein-bound particles
T1071	corecomposition 55834 55847	albumin-bound
T1073	nanoparticle 55852 55904	paclitaxel formulated as albumin-bound nanoparticles
T1075	particlediameter 55948 55963	130 nanometers.
T1077	activeingredient 55965 55975	Paclitaxel
T1079	tradename 56039 56047	ABRAXANE
T1081	inactiveingredient 56148 56163	Sodium Chloride
T1083	routeofadministration 56188 56199	intravenous
T1085	activeingredient 56251 56261	paclitaxel
T1087	corecomposition 56278 56286	albumin)
T1089	corecomposition 56321 56328	albumin
T1091	inactiveingredient 56341 56357	sodium caprylate
T1093	inactiveingredient 56362 56389	sodium acetyltryptophanate)
T1095	nanoparticle 56455 56504	paclitaxel formulated as albumin-bound particles.
T1097	tradename 56505 56513	ABRAXANE
T1099	tradename 56556 56564	ABRAXANE
T1101	activeingredient 56568 56578	paclitaxel
T1103	chemoclass 56582 56604	microtubule inhibitor.
T1105	activeingredient 56628 56638	paclitaxel
T1107	activeingredient 56642 56643	5
T1109	activeingredient 56646 56651	20- 1
T1111	activeingredient 56652 56653	2
T1113	activeingredient 56656 56657	4
T1115	activeingredient 56658 56659	7
T1117	activeingredient 56662 56664	10
T1119	activeingredient 56667 56700	13 -hexahydroxytax-11-en-9-one 4
T1121	activeingredient 56701 56742	10-diacetate 2-benzoate 13-ester with (2R
T1123	activeingredient 56743 56775	3S)-N-benzoyl-3-phenylisoserine.
T1125	activeingredient 56777 56787	Paclitaxel
T1127	activeingredient 56827 56837	Paclitaxel
T1129	activeingredient 56908 56918	C47H51NO14
T1131	molecularweight 56945 56952	853.91.
T1133	tradename 57097 57105	ABRAXANE
T1135	chemoclass 57111 57132	microtubule inhibitor
T1137	activeingredient 57435 57445	Paclitaxel
T1139	activeingredient 57643 57653	paclitaxel
T1141	tradename 57695 57703	ABRAXANE
T1143	dose 57722 57737	80 to 375 mg/m2
T1145	activeingredient 57813 57823	paclitaxel
T1147	tradename 57827 57838	ABRAXANE. 
T1149	routeofadministration 57848 57859	intravenous
T1151	tradename 57878 57886	ABRAXANE
T1153	activeingredient 57888 57898	paclitaxel
T1155	dose 58146 58161	80 to 300 mg/m2
T1157	activeingredient 58190 58200	paclitaxel
T1159	tradename 58205 58213	ABRAXANE
T1161	routeofadministration 58250 58261	intravenous
T1163	dose 58307 58316	260 mg/m2
T1165	tradename 58317 58325	ABRAXANE
T1167	dose 58405 58414	175 mg/m2
T1169	activeingredient 58415 58425	paclitaxel
T1171	tradename 58540 58548	ABRAXANE
T1173	activeingredient 58558 58568	paclitaxel
T1175	tradename 58657 58665	ABRAXANE
T1177	activeingredient 58712 58722	paclitaxel
T1179	activeingredient 58882 58892	paclitaxel
T1181	tradename 58933 58941	ABRAXANE
T1183	activeingredient 58973 58983	paclitaxel
T1185	activeingredient 59054 59064	paclitaxel
T1187	tradename 59070 59078	ABRAXANE
T1189	activeingredient 59107 59117	paclitaxel
T1191	activeingredient 59218 59228	paclitaxel
T1193	activeingredient 59396 59407	paclitaxel.
T1195	volumeofdistribution 59459 59465	1741 L
T1197	activeingredient 59572 59583	paclitaxel.
T1199	activeingredient 59673 59683	paclitaxel
T1201	activeingredient 59860 59870	paclitaxel
T1203	activeingredient 60345 60355	paclitaxel
T1205	dose 60570 60585	80 to 300 mg/m2
T1207	activeingredient 60615 60625	paclitaxel
T1209	clearance 60638 60653	13 to 30 L/h/m2
T1211	plasmahalflife 60699 60714	13 to 27 hours.
T1213	dose 60746 60755	260 mg/m2
T1215	tradename 60765 60773	ABRAXANE
T1217	activeingredient 61224 61234	paclitaxel
T1219	tradename 61245 61253	ABRAXANE
T1221	activeingredient 61500 61511	paclitaxel.
T1223	activeingredient 61748 61758	paclitaxel
T1225	activeingredient 61798 61808	paclitaxel
T1227	activeingredient 62013 62023	paclitaxel
T1229	tradename 62327 62335	ABRAXANE
T1231	indication 62453 62494	metastatic adenocarcinoma of the pancreas
T1233	activeingredient 62814 62824	paclitaxel
T1235	tradename 62835 62843	ABRAXANE
T1237	activeingredient 63053 63063	paclitaxel
T1239	tradename 63172 63180	ABRAXANE
T1241	activeingredient 63446 63457	paclitaxel.
T1243	tradename 63499 63507	ABRAXANE
T1245	tradename 63594 63602	ABRAXANE
T1247	indication 63629 63634	NSCLC
T1249	activeingredient 63682 63692	paclitaxel
T1251	activeingredient 63909 63920	paclitaxel.
T1253	tradename 63961 63969	ABRAXANE
T1255	tradename 64023 64031	ABRAXANE
T1257	tradename 64200 64208	ABRAXANE
T1259	activeingredient 64232 64242	Paclitaxel
T1261	tradename 64356 64364	ABRAXANE
T1263	activeingredient 64457 64467	paclitaxel
T1265	corecomposition 64482 64495	albumin-bound
T1267	dose 64926 64940	3 and 12 mg/m2
T1269	frequency 64940 64945	/week
T1271	activeingredient 65154 65164	paclitaxel
T1273	corecomposition 65179 65192	albumin-bound
T1275	dose 65262 65270	54 mg/m2
T1277	dose 65286 65295	175 mg/m2
T1279	indication 65334 65358	Metastatic Breast Cancer
T1281	tradename 65530 65538	ABRAXANE
T1283	indication 65542 65567	metastatic breast cancer.
T1285	tradename 65615 65623	ABRAXANE
T1287	dose 65678 65687	175 mg/m2
T1289	indication 65708 65733	metastatic breast cancer.
T1291	dose 65771 65780	300 mg/m2
T1293	indication 65825 65850	metastatic breast cancer.
T1295	indication 66042 66067	metastatic breast cancer.
T1297	tradename 66106 66114	ABRAXANE
T1299	dose 66128 66137	260 mg/m2
T1301	activeingredient 66172 66182	paclitaxel
T1303	dose 66196 66205	175 mg/m2
T1305	tradename 66811 66819	ABRAXANE
T1307	activeingredient 67040 67050	paclitaxel
T1309	indication 67233 67257	Metastatic Breast Cancer
T1311	tradename 67265 67273	ABRAXANE
T1313	dose 67274 67283	260 mg/m2
T1315	activeingredient 67285 67295	Paclitaxel
T1317	dose 67306 67315	175 mg/m2
T1319	indication 68282 68308	Non-Small Cell Lung Cancer
T1321	indication 68415 68441	non-small cell lung cancer
T1323	tradename 68453 68461	ABRAXANE
T1325	activeingredient 68497 68507	paclitaxel
T1327	indication 68600 68627	non-small cell lung cancer.
T1329	tradename 68629 68637	ABRAXANE
T1331	routeofadministration 68661 68672	intravenous
T1333	dose 68711 68720	100 mg/m2
T1335	activeingredient 68766 68776	Paclitaxel
T1337	routeofadministration 68810 68821	intravenous
T1339	dose 68857 68866	200 mg/m2
T1341	routeofadministration 68985 68998	intravenously
T1343	tradename 69049 69058	ABRAXANE/
T1345	activeingredient 69058 69068	paclitaxel
T1347	tradename 69659 69668	ABRAXANE/
T1349	activeingredient 69775 69785	paclitaxel
T1351	indication 69990 70016	Non-Small Cell Lung Cancer
T1353	tradename 70053 70061	ABRAXANE
T1355	dose 70063 70072	100 mg/m2
T1357	frequency 70073 70080	weekly)
T1359	activeingredient 70105 70115	Paclitaxel
T1361	dose 70127 70136	200 mg/m2
T1363	frequency 70137 70151	every 3 weeks)
T1365	indication 70669 70699	Adenocarcinoma of the Pancreas
T1367	tradename 70800 70808	ABRAXANE
T1369	indication 70884 70926	metastatic adenocarcinoma of the pancreas.
T1371	tradename 71564 71573	ABRAXANE/
T1373	tradename 71854 71863	ABRAXANE/
T1375	tradename 71884 71892	ABRAXANE
T1377	dose 71893 71902	125 mg/m2
T1379	routeofadministration 71909 71920	intravenous
T1381	dose 71973 71983	1000 mg/m2
T1383	routeofadministration 71990 72001	intravenous
T1385	dose 72119 72129	1000 mg/m2
T1387	routeofadministration 72136 72147	intravenous
T1389	dose 72247 72257	1000 mg/m2
T1391	indication 73269 73299	Adenocarcinoma of the Pancreas
T1393	tradename 73318 73327	ABRAXANE(
T1395	dose 73327 73337	125 mg/m2)
T1397	tradename 73958 73966	ABRAXANE
T1399	activeingredient 75639 75649	paclitaxel
T1401	tradename 76240 76248	ABRAXANE
T1403	tradename 76439 76447	ABRAXANE
T1405	tradename 76574 76582	ABRAXANE
T1407	tradename 77054 77062	ABRAXANE
T1409	tradename 77310 77318	ABRAXANE
T1411	company 77672 77691	Celgene Corporation
T1413	tradename 77711 77719	ABRAXANE
T1415	company 77750 77768	Abraxis BioScience
T1417	company 77770 77774	LLC.
T1419	company 77787 77805	Abraxis BioScience
T1421	company 77807 77811	LLC.
T1423	company 77835 77853	Abraxis BioScience
T1425	company 77855 77858	LLC
T1427	company 77891 77911	Celgene Corporation.
T1429	tradename 78003 78013	 ABRAXANE
T1431	activeingredient 78031 78041	paclitaxel
T1433	corecomposition 78094 78107	albumin-bound
T1435	tradename 78167 78175	ABRAXANE
T1437	tradename 78328 78347	ABRAXANE? ABRAXANE
T1439	indication 78502 78528	non-small cell lung cancer
T1441	tradename 78771 78779	ABRAXANE
T1443	tradename 78839 78850	ABRAXANE? 
T1445	tradename 78865 78873	ABRAXANE
T1447	tradename 78979 78991	ABRAXANE.  
T1449	tradename 79037 79046	ABRAXANE?
T1451	tradename 79066 79074	ABRAXANE
T1453	tradename 79264 79284	ABRAXANE.  ABRAXANE
T1455	tradename 79420 79428	ABRAXANE
T1457	tradename 79503 79512	ABRAXANE.
T1459	tradename 79672 79683	ABRAXANE. 
T1461	tradename 79743 79751	ABRAXANE
T1463	tradename 79836 79844	ABRAXANE
T1465	tradename 80129 80140	ABRAXANE? 
T1467	tradename 80171 80179	ABRAXANE
T1469	tradename 80309 80320	ABRAXANE. 
T1471	tradename 80388 80399	ABRAXANE. 
T1473	tradename 80436 80444	ABRAXANE
T1475	tradename 80472 80480	ABRAXANE
T1477	routeofadministration 80505 80516	intravenous
T1479	tradename 80603 80615	ABRAXANE.  
T1481	tradename 80653 80673	ABRAXANE? ABRAXANE
T1483	tradename 80755 80763	ABRAXANE
T1485	tradename 81026 81034	ABRAXANE
T1487	tradename 81209 81217	ABRAXANE
T1489	tradename 81458 81466	ABRAXANE
T1491	tradename 81711 81719	ABRAXANE
T1493	tradename 81790 81798	ABRAXANE
T1495	tradename 82460 82471	ABRAXANE. 
T1497	tradename 82692 82703	ABRAXANE. 
T1499	tradename 82886 82897	ABRAXANE. 
T1501	tradename 83014 83022	ABRAXANE
T1503	tradename 83139 83150	ABRAXANE? 
T1505	activeingredient 83169 83179	paclitaxel
T1507	corecomposition 83196 83204	albumin)
T1509	corecomposition 83232 83239	albumin
T1511	inactiveingredient 83252 83268	sodium caprylate
T1513	inactiveingredient 83273 83300	sodium acetyltryptophanate)
T1515	company 83436 83455	Celgene Corporation
T1517	tradename 83474 83482	ABRAXANE
T1519	company 83513 83531	Abraxis BioScience
T1521	company 83533 83537	LLC.
T1523	company 83550 83568	Abraxis BioScience
T1525	company 83570 83574	LLC.
T1527	company 83598 83616	Abraxis BioScience
T1529	company 83618 83621	LLC
T1531	company 83654 83674	Celgene Corporation.
